In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
High risk for psychiatric disorders seen before dementia diagnosis
Oct 20, 2023
The findings were consistent regardless of dementia subtype.
Patients with dementia less likely to receive intensive care after hospital transfer
Jan 04, 2024
The authors say that future work should focus on determining whether transfers are needed.
Composite inflammatory biomarker linked to dementia risk
Jul 21, 2023
Small but significant associations were seen between elevated biomarker levels and worsened cognitive performance.
Stress, depression linked to MCI, Alzheimer’s disease
Oct 20, 2023
Chronic stress and depression are independent risk factors and have an additive effect when combined.
Earlier onset of A-Fib linked to risk of developing all-cause dementia
Nov 10, 2023
Younger age at A-Fib onset was linked to increased risks of all-cause and vascular dementia and Alzheimer disease.
Risk for adverse outcomes increased with antipsychotic use in dementia
Apr 19, 2024
Risks increased for stroke, venous thromboembolism, myocardial infarction, heart failure, fracture, pneumonia and acute kidney injury.
Panel of 48 CSF proteins complements existing Alzheimer’s biomarkers
Sep 07, 2023
The CSF 48 panel plus existing biomarkers significantly improved the diagnostic performance for the outcomes studied.
Early-onset Alzheimer’s disease patients in rural areas lack specialty care
Aug 09, 2022
Rural patients are more likely to receive a diagnosis and treatment from primary care providers.
BMI declines seen seven years before cognitive impairment diagnosis
Nov 02, 2022
However, after diagnosis, BMI declines at the same pace in people who develop or do not develop dementia.